Strong Q1 sales of $137.3M showcase Madrigal Pharmaceuticals, Inc.'s Rezdiffra's growth in non-cirrhotic NASH. Click for my ...

Q2 2025 Management View William J. Sibold, CEO, highlighted a "productive last few months" focused on driving the launch and building for the future, noting, "Rezdiffra’s quarterly run rate now ...

Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the Canaccord Genuity 45th Annual Growth Conference on Tuesday, Aug. 12, 2025 at 10:30 A.M. EDT. The ...

The 9th MASH Drug Development Summit is the essential forum for pharmaceutical giants and innovative biotechs dedicated to ...

Madrigal Pharmaceuticals inks $2.1 billion deal with Chinese firm for MASH treatment, aiming to enhance Rezdiffra's efficacy ...

Madrigal Pharmaceuticals (MDGL) stock gains as the company's Q2 2025 results exceed expectations with a 15-fold surge in ...

Madrigal will study SYH2086 in combination with Rezdiffra for metabolic dysfunction-associated steatohepatitis, aiming for clinical trials in early 2026.

In the pivotal Phase 3 MAESTRO-NASH biopsy trial, Rezdiffra achieved both fibrosis improvement and NASH resolution primary endpoints, and 80% of patients treated with Rezdiffra 100 mg experienced ...

Fourth-quarter and full-year 2024 Rezdiffra net sales of $103.3 million and $180.1 million, respectivelyAs of year-end 2024, more than 11,800 patients on Rezdiffra Reports cash, cash equivalents ...

Madrigal Pharmaceuticals stock jumps 11% after securing a new U.S. patent for Rezdiffra's dosing, reinforcing exclusivity through 2044.

Rezdiffra shouldn't be taken by patients with a more advanced form of liver disease called decompensated cirrhosis, the FDA said, and the drug may interact with cholesterol-lowering statins, so ...